Preview Newsletter
Xarelto Media Monitoring Week of 5/8 - do not delete
-
Lawsuit Help Center Announces Full Dedication to Assisting Xarelto Victims
May 4, 2015 | Lawsuitsettlementnews.com
By MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they are dedicated to helping victims, or their family members, who have suffered complications or even death as a result of using the blood thinner, Xarelto. -
Bayer Confident on Xarelto Sales, Despite Mounting Lawsuits
May 7, 2015 | The Xarelto Lawsuit
By Bernstein Liebhard LLP
Bayer is expecting a 30% jump in sales of Xarelto this year, even though it faces a growing number of product liability lawsuits involving the anticoagulant. According to the company’s most recent financial release, the medication racked up more than $1 billion in sales during the first quarter of 2015. -
Xarelto Litigation Proceeding in MDL and Mass Tort
May 1, 2015 | Legal Examiner - New York
By Roopal Luhana
The most recent status conference concerning the Xarelto MDL, currently proceeding in the Eastern District of Louisiana, took place on April 1, 2015. The U.S. Judicial Panel on Multidistrict Litigation (JPML) established the MDL in December 2014. -
Xarelto Lawsuit Blames Blood Thinner for Gastrointestinal Bleeding
May 1, 2015 | Top Class Actions
By Ashley Vanover
Drug giants Bayer and Janssen Pharmaceuticals are named as defendants in a recently filed lawsuit alleging that they concealed their knowledge from the public and medical community that the new generation blood thinner, Xarelto, can cause life-threatening, irreversible bleeds. -
Xarelto Manufacturer Knew of Risks
May 1, 2015 | Jones Ward PLC Blog
By Staff
Johnson and Johnson, Bayer, and the Janssen Pharmaceutical Research and Development Division of Johnson and Johnson, are being sued in part on the basis that they produced, manufactured, and marketed a defective drug when they knew of the risks involved with taking Xarelto. -
Xarelto Lawsuits Over Bleeding Problems Not Expected to Slow Sales, According to Bayer
May 1, 2015 | About Lawsuits
By Austin Kirk
While a growing number of Xarelto lawsuits continue to be filed on behalf of individuals who have suffered severe and often fatal bleeding problems, Bayer reports that it anticipates sales for the controversial anticoagulant will continue to grow, with expected growth of 30% this year. -
Drug warnings withheld: Blood thinner causes uncontrolled bleeding
May 1, 2015 | Natural Health 365
By Allison Reed
Yet another highly marketed blood thinner medication, Xarelto, has been making headlines for its life-threatening side effects. In fact, Xarelto may be one of the most dangerous blood thinners to date – as there is no antidote for the internal bleeding it can cause individuals who take it. -
Xarelto Lawsuit Added to Multidistrict Litigation
May 3, 2015 | Injury Lawyer News
By Stephanie Reid
On April 23, 2015, a new Xarelto lawsuit was filed in the ongoing multidistrict litigation (MDL) against the makers and manufacturers of the blood thinning agent: Janssen Pharmaceuticals and Johnson & Johnson. This lawsuit is one of dozens filed by injured plaintiffs or their families, all of which have alleged severe, unforeseen side effects associated with the drug. -
Philadelphia Court System Establishes Xarelto Mass Tort
May 4, 2015 | Righting Injustice
By Jennifer Walker-Journey
Philadelphia’s court system has established a new Xarelto mass tort involving about 170 plaintiffs alleging uncontrollable and sometimes fatal bleeding with the blood thinning drug. The lawsuits name Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals as the defendants. -
Ind. Man Sues Pharmaceutical Giants for Xarelto Bleeding Injury
May 4, 2015 | Top Class Actions
By Amanda Antell
Indiana plaintiff Frederick B. is suing Bayer and Janssen Pharmaceuticals for the injuries he allegedly sustained from their anticoagulant product. Frederick claims that as a direct result of using Xarelto, he developed severe gastrointestinal bleeding. -
Xarelto Medication Lawsuits Pending in MDL Reach 402 as of April 17, 2015
May 5, 2015 | American Injury Attorney Group
By Staff
Lawsuits involving Janssen’s Xarelto medication continue to move forward. According to court records, 100 Xarelto lawsuits have been filed since March 16, 2015 in the Xarelto multidistrict litigation (MDL) in the U.S. District Court, Eastern District of Louisiana. According to the U.S. Judicial Panel on Multidistrict Litigation, as of April 17, 2015, 402 lawsuits are pending in the Xarelto MDL. -
The Choice between Xarelto Bleeding and Stroke Risks
May 6, 2015 | Legal Examiner - Pennsylvania
By Gregory Spizer
People with atrial fibrillation have an increased risk of suffering a stroke. Taking blood thinner drugs can decrease the risk, but some of these medications are not without the risks of internal bleeding. Popular blood-thinning drug Xarelto is prescribed to patients to prevent blood clots and prevent strokes. Most patients do not know that Xarelto may also cause irreversible internal bleeding, often resulting in extended hospitalizations and death. -
Xarelto Cases Have Been Consolidated in Louisiana
May 6, 2015 | DGMS Law
By Staff
You may have seen the commercials for Xarelto – the ones with Arnold Palmer, Kevin Nealon, and and Brian Vickers. Xarelto is a blood thinner used to prevent blood clots. It’s a fairly new drug and, unfortunately, has some dangerous side effects. The worst of these is uncontrolled bleeding, which can be fatal. -
Research Suggests Gastrointestinal Xarelto Side Effects Worse Than Warfarin’s
May 7, 2015 | Injury Lawyer News
By Sarah May
According to a recently published research study, popular anticoagulant drugs Xarelto and Pradaxa may pose a heightened risk of serious gastrointestinal bleeding in patients who choose them instead of more traditional blood thinning medications such as warfarin.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Full Text of Stories Below
-
Lawsuit Help Center Announces Full Dedication to Assisting Xarelto Victims
May 4, 2015 | Lawsuitsettlementnews.com
By MT Services LLC
MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that they are dedicated to helping victims, or their family members, who have suffered complications or even death as a result of using the blood thinner, Xarelto. This announcement comes just after new court documents were issued in two courts – the U.S. District Court in the Eastern District of Louisiana and the Philadelphia Court of Common Pleas in Pennsylvania. The two new court documents were issued in consolidated litigations over Xarelto in both states listed. Court documents dated March 23rd in the Philadelphia Court of Common Pleas show that approval came for a Master Long Form Complaint, indicating that plaintiffs with potential claims who want to file suit in that state will now be able to use the approved Master Long Form Complaint in Pennsylvania’s mass tort proceeding for Xarelto (In Re: Xarelto Litigation, Case ID 150102349). A court order dated March 24th in the U.S. District Court in the Eastern District of Louisiana – where the Xarelto federal multidistrict litigation (MDL) is underway – indicates that plaintiffs will now be able to file their cases directly in the proceedings (In Re: Xarelto Products Liability Litigation, No. 2592).
Currently, there are 402 filed lawsuits over Xarelto in the federal litigation in Louisiana, with an additional 204 known cases with similar claims pending in Pennsylvania’s mass tort proceeding, according to court documents. The lawsuits allege serious uncontrollable bleeding events and even death as a result of using the blood thinner, Xarelto. According to Drug Watch, lawsuits indicate that hundreds of patients have died as a result of bleeding events caused by Xarelto, and in 2012, the FDA reported that three times more people died while on the blood thinner, Xarelto, in comparison to warfarin due to adverse bleeding events. Now, the lawsuits are growing as the litigation picks up steam, and MTS is prepared to assist patients who believe they may have a potential claim against Xarelto’s maker, Bayer and Johnson & Johnson’s Janssen Pharmaceutical Division.
Patients or loved ones who are in need of some lawsuit guidance can apply for a free case evaluation by visiting: http://www.lawsuitsettlementnews.com/pradaxa-all-blood-thinner-cases
Plaintiffs who already have an attorney and have filed a lawsuit and need lawsuit money or a lawsuit funding cash advance, not to be confused with a lawsuit loan or pre-settlement loan, can contact Lawsuit Settlement News. Injured parties from Pradaxa or Xarelto usage and/or complications can apply for up to $50K in pre-settlement or settlement lawsuit funding. For a full list of the services that the company provides, visit: http://www.lawsuitsettlementnews.com/about-our-products-and-services
Victims, or their loved ones, who have been injured by Xarelto or Pradaxa and need lawsuit help, including finding an experienced Pradaxa or Xarelto law firm or applying for a cash advance on a Pradaxa or Xarelto lawsuit, can call toll-free to speak with a live agent at: 877.571.0405.
Plaintiffs may also fill out a quick application online at: www.lawsuitsettlementnews.com and an agent will respond shortly.
Disclaimer: MT Services LLC, operator of Lawsuitsettlementnews.com, is not a law firm and cannot provide legal advice on the plaintiff’s case; however, MTS works with lawyers involved in mass tort litigations who are willing to provide a free legal consultation at the consumer’s request. For a list of full disclosures, please visit the company’s website disclosure page.
-
Bayer Confident on Xarelto Sales, Despite Mounting Lawsuits
May 7, 2015 | The Xarelto Lawsuit
By Bernstein Liebhard LLP
Bayer is expecting a 30% jump in sales of Xarelto this year, even though it faces a growing number of product liability lawsuits involving the anticoagulant. According to the company’s most recent financial release, the medication racked up more than $1 billion in sales during the first quarter of 2015.
“Xarelto expanded its leading position among the new oral anticoagulants, particularly in Europe,” the company’s first quarter financial report states. “Business with Xarelto also developed very positively in the United States, where it is marketed by a subsidiary of Johnson & Johnson.”
Bayer also acknowledged that it had been named a defendant in at least 500 Xarelto lawsuits that have been filed in U.S. courts on behalf of individuals who allegedly suffered serious episodes of internal bleeding and other complications due to its use, along with at least five similar class actions in Canada. Additional filings are anticipated, according to the company.Xarelto Litigation
Bayer introduced Xarelto to the U.S. market in 2011, promising that it would be easier to use than warfarin, a blood thinner that has been in use for decades. But over the past year, more and more patients have come forward to fileXarelto lawsuits that question the veracity of these claims. Among other things, they point out that there currently exists no approved antidote to reverse Xarelto bleeding. While all anticoagulants pose a risk of internal hemorrhaging, bleeding associated with warfarin can be stopped via the administration of vitamin K.
The majority of U.S. Xarelto cases have been filed in a multidistrict litigation that is currently underway in the U.S. District Court, Eastern District of Louisiana. Just over 220 similar claims are pending in a mass tort program that was established earlier this year in Pennsylvania’s Philadelphia Court of Common Pleas. All of the complaints similarly allege that Xarelto was wrongly marketed as a superior alternative to warfarin and places patients at risk for uncontrollable internal bleeding, as well as related complications such as strokes and blood clots.
Xarelto patients may be entitled to compensation if they experienced internal bleeding or related injuries while using the medication. If you would like to discuss filing a Xarelto lawsuit with an experienced attorney, please contact Bernstein Liebhard LLP today by calling (888) 979-1182
-
Xarelto Litigation Proceeding in MDL and Mass Tort
May 1, 2015 | Legal Examiner - New York
By Roopal Luhana
The most recent status conference concerning the Xarelto MDL, currently proceeding in the Eastern District of Louisiana, took place on April 1, 2015. The U.S. Judicial Panel on Multidistrict Litigation (JPML) established the MDL in December 2014.
According to minutes from the meeting, both the plaintiffs and the defendants are working toward coordination between the established MDL and state court actions, which includes a Xarelto mass tort in Pennsylvania.
More Than 300 Xarelto Lawsuits Proceeding in MDL
This early in the proceedings, the parties are still busy completing forms, discussing software for fact sheets, creating and reviewing various orders (preservation order, document production protocol order, protective order, etc.), and establishing a “science day” where the medical facts of Xarelto will be explained and explored. The next status conference is scheduled for May 13, 2015.
At last count, more than 300 Xarelto lawsuits had been filed in the MDL. An additional 170 or so were pending in the Pennsylvania mass tort, which was established in January 2015 by Philadelphia Court of Common Pleas Administrative Judge Kevin Dougherty.
In most all cases, plaintiffs claim that after taking Xarelto, they suffered serious side effects, including uncontrollable bleeding. Some lawsuits have been filed by the families of victims who died due to Xarelto bleeding.
Xarelto Advertised as “More Convenient”
The FDA approved Xarelto for reducing the risk of blood clots in those going through hip and knee replacement surgery in 2011, and later that same year to reduce the risk of stroke in patients with non-valvular atrial fibrillation. They added approval for the treatment of deep vein thrombosis and pulmonary embolism in 2012.
Xarelto is one of the so-called “new generation” anticoagulants, along with Pradaxa, which was approved in 2010. Both were advertised as alternatives to warfarin, the leading blood thinner for decades, because they didn’t require dietary changes or regular blood monitoring.
Later studies questioned this logic for Xarelto, as it was discovered that Japanese patients and those with kidney problems could have benefitted from blood monitoring. It would have indicated which ones were at risk of uncontrolled bleeding.
The Institute for Safe Medication Practices also noted in its QuarterWatch publication for the first quarter of 2012, that even during the FDA’s approval process, reviewers raised concerns about the once-a-day dosing of Xarelto, saying that the drugs’ “peaks and troughs” could be eliminated with twice-a-day dosing.
Once it was on the market, Xarelto was linked to serious side effects, including gastrointestinal bleeding that led to hospitalization and in some cases, death. In the year leading up to June 30, 2012, over 1,000 cases were reported to the FDA, including 65 deaths. In the first quarter of 2013, the number of adverse events linked to Xarelto overtook those of Pradaxa.
Companies Failed to Provide Adequate Warnings
Plaintiffs who are involved in Xarelto litigation claim the manufacturers, Janssen Pharmaceuticals and Bayer, exaggerated the benefits of the drug when advertising it to consumers, while downplaying the potential risks.
They add that the companies failed to provide adequate warnings about the dangers associated with Xarelto, including the fact that there was no readily available antidote for excessive bleeding. Whereas doctors can stop bleeding caused by warfarin with injections of vitamin K, they have no similar solution for Xarelto bleeding. Patients suffering such bleeding have a higher risk of lasting injury and death.
Link to blog: http://newyork.legalexaminer.com/defective-dangerous-products/xarelto-litigation-proceeding-in-mdl-and-mass-tort/
-
Xarelto Lawsuit Blames Blood Thinner for Gastrointestinal Bleeding
May 1, 2015 | Top Class Actions
By Ashley Vanover
Drug giants Bayer and Janssen Pharmaceuticals are named as defendants in a recently filed lawsuit alleging that they concealed their knowledge from the public and medical community that the new generation blood thinner, Xarelto, can cause life-threatening, irreversible bleeds.
A Colorado resident has filed a lawsuit against the manufacturer Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson and the co-marketer of Xarelto) and Bayer Healthcare AG, alleging these companies failed to adequately warn about the lack of a Xarelto antidote to reverse uncontrolled bleeding caused by Xarelto.
According to the Xarelto lawsuit, plaintiff Lydia S. used Xarelto beginning in May 2012 to prevent deep vein thrombosis after undergoing hip replacement surgery. A week after initially taking Xarelto, Lydia was hospitalized for acute gastrointestinal bleeding as well as other severe injuries that were a direct result of Bayer and Janssen Pharmaceutical’s omissions relating to Xarelto side effects, the Xarelto lawsuit alleges.
Lydia claims the drug should not be sold and that Bayer and Janssen Pharmaceutical failed to provide warnings or other information that accurately reflected the symptoms, scope, and severity of Xarelto side effects and Xarelto bleeding risks. Lydia is also seeking for her case to be included in the Xarelto multidistrict litigation (MDL) currently pending in the U.S. District Court for the Eastern District of Louisiana.What is Xarelto?
Xarelto (rivaroxaban) is one of the latest generation of anticoagulant drugs, designed to treat patients at risk of deep vein thrombosis (the formation of blood clots deep under the skin surface). Specifically, it is prescribed for those patients, like Lydia, who have undergone hip or knee replacements.
Xarelto, along with two similar medications (Pradaxa and Eliquis), was intended to replace warfarin, a a blood thinner medication that has been the standard treatment for this condition since the early 1950s. The purported advantage of Xarelto and similar medications is a reduced need for patient monitoring; these prescriptions have far fewer drug and food interactions than warfarin, though the cost per dose to the patient is substantially higher.Xarelto Bleeding Issues
The most serious problem associated with Xarelto and similar medications is fatal hemorrhaging. When a patient on the medication starts bleeding from even a minor injury (including a bump on the head), there is virtually no way to stop it.
The reason for this lies in the drug’s mechanism of action. Blood coagulation is dependent on the action of Vitamin K (naturally occurring in leafy greens and vegetables) in order to produce the clotting agent, thrombin. Warfarin disables Vitamin K, so any serious bleeding can be halted with high dosages of this vitamin. Xarelto prevents the production of Vitamin K altogether; therefore, once a patient starts suffering from Xarelto bleeding, there is virtually no way to stop it.Xarelto Injury Lawsuits
The Xarelto Injury lawsuit is seeking compensatory and punitive damages arising from ingestion of Xarelto as well as the defendants’ disregard in misleading the medical community and consumers in favor of increasing sales. The filed complaint indicates a demand for a jury trial for this case.
The Xarelto Lawsuit is Case No. 2:15-cv-01261 in the U.S. District Court for the Eastern District of Louisiana, and the Xarelto MDL is In re: Xarelto® (Rivaroxaban) Products Liability Litigation, Case No: 14-md-2592, MDL 2592, in the U.S. District Court for the Eastern District of Louisiana.
Link to blog: http://topclassactions.com/lawsuit-settlements/lawsuit-news/54753-xarelto-lawsuit-blames-blood-thinner-for-gastrointestinal-bleeding/
-
Xarelto Manufacturer Knew of Risks
May 1, 2015 | Jones Ward PLC Blog
By Staff
Johnson and Johnson, Bayer, and the Janssen Pharmaceutical Research and Development Division of Johnson and Johnson, are being sued in part on the basis that they produced, manufactured, and marketed a defective drug when they knew of the risks involved with taking Xarelto. These risks involved severe bleeding, heart attacks, paralysis and death. Had potential patients and their doctors been adequately warned about these potential side effects of Xarelto, they would have likely chosen not to take Xarelto. Johnson and Johnson, Bayer and the Janssen Pharmaceutical Research and Development Division of Johnson and Johnson chose to keep these potential side effects hidden from the public.
Xarelto was promoted as an alternative to coumadin (warfarin), the leading anticoagulant preferred by doctors and patients for decades. While warfarin sometimes led to gastrointestinal bleeding or pulmonary bleeding, there was an antidote that could be used to stop the uncontrollable bleeding side effects. In the case of Xarelto bleeding, there was no such antidote to remedy Xarelto side effects.
Xarelto was defective because it led to excessive and dangerous bleeds which could be fatal. The producers of Xarelto allegedly failed to adequately warn of this serious side effect of their blood thinner. Janssen, Johnson and Johnson and Bayer put an alleged defective drug into the market when they knew, or should have known, that it could cause uncontrollable internal bleeding and could be fatal.
Because the Xarelto Defendants had information that their drug could cause uncontrollable internal bleeding and death, but did not adequately warn physicians and their patients of these serious adverse consequences, the Xarelto Defendants may have opened themselves up to punitive damages which go above and beyond the damages normally awarded in a civil lawsuit. In instances where a defendant’s conduct is particularly reprehensible. In fact, punitive damages are quasi – criminal and are awarded to punish a defendant in a civil lawsuit.
If you or a loved one suffered severe, uncontrollable bleeding as a result of taking Xarelto, please contact the lawyers at Jones Ward PLC for a free case evaluation. You can call us toll free at 1-888-595-2922 or send us an email.
Link to blog: http://www.jonesward.com/xarelto-manufacturer-knew-of-risks/
-
Xarelto Lawsuits Over Bleeding Problems Not Expected to Slow Sales, According to Bayer
May 1, 2015 | About Lawsuits
By Austin Kirk
While a growing number of Xarelto lawsuits continue to be filed on behalf of individuals who have suffered severe and often fatal bleeding problems, Bayer reports that it anticipates sales for the controversial anticoagulant will continue to grow, with expected growth of 30% this year.
According to Bayer’s first quarter financial report (PDF), there are now more than 500 complaints pending throughout the U.S. involving allegations that the drug maker failed to adequately warn about the potential risk of uncontrollable bleeding with Xarelto. In addition, at least five Xarelto class action lawsuits have been filed in Canada.
Despite the mounting litigation, Bayer reports that Xarelto sales have exceeded half a billion dollars in the first quarter alone, setting it on an easy path to blockbuster status again this year, and dwarfing sales of competitors that are part of a new generation of novel oral anticoagulants, such as Pradaxa and Eliquis.
Bayer also reported that estimated sales growth for Xarelto is should be higher than expected in 2015, increasing from a previous prediction of 20% growth to 30%.Internal Bleeding Problems on Xarelto
Xarelto (rivaroxoaban) was introduced in 2011 as a superior replacement for Coumadin (warfarin), which has been the “go-to” medication for prevention of blood clots and strokes among patients with atrial fibrillation for decades. It was the second member of of this new generation introduced, and quickly grew to become the most widely used.
While all blood thinners carry a risk of bleeding injury, Xarelto has been linked to a surprising number of bleeding problems as more and more patients are switched to the novel anticoagulant.
Unlike warfarin, for which the blood thinning effects of the medication can be quickly reversed in the case of an emergency, there is no approved antidote for Xarelto, which has left many doctors helpless to stop hemorrhages or other bleeding experienced by users. While Bayer is currently working on obtaining an effective reversal agent, lawsuits have alleged that the drug never should have been introduced without an antidote or stronger warnings for doctors.
Sales of Xarelto have been fueled by claims that it is easier to use than warfarin, which requires frequent blood monitoring. While the drug makers have promoted a one-size fits all approach, recent studies have raised questions about whether many of the bleeding problems may actually have been avoided if Bayer had recommended blood monitoring with Xarelto to help doctors identify patients at the greatest risk bleeds.Xarelto Bleeding Lawsuits
In December 2014, amid the growing number of injury and wrongful death lawsuits over Xarelto filed throughout the federal court system, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established consolidated pretrial proceedings for the cases.
The Xarelto litigation is currently centralized before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. Given the nearly identical allegations raised in the cases, the lawsuits have been consolidated to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts.
One of the most recently filed lawsuits involves a complaint (PDF) brought this week by Frank Peck, which indicates that his wife, Ann, died after suffering uncontrollable internal bleeding and a hemorrhagic stroke. Ann Peck was prescribed Xarelto in late March 2013, and was dead by May 4, 2013.
“Defendants routinely marketed Xarelto as a ‘one size fits all’ drug,” the lawsuit states.”In their fervent marketing of Xarelto, Defendants’ misinformed patients and their healthcare providers as to the necessity to routinely monitor any patient requiring a blood thinning agent.”
Peck is pursuing claims against the drug makers for failure to warn, designing a defective drug, negligence, negligent design, negligent misrepresentation, breach of warranty, fraud, and violating consumer protection laws, seeking both compensatory and punitive damages.
It is ultimately expected that several thousand complaints will be centralized before Judge Fallon, as Xarelto bleeding lawyers continue to review and file lawsuits.
As part of the coordinated pretrial proceedings before Judge Fallon, it is expected that a small group of cases will be scheduled for early trial dates in the MDL. Known as “bellwether” cases, these trials will be designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the U.S. litigation.
While the outcome of any early trial dates will not be binding in other cases, they may help the drug makers reach Xarelto settlements to avoid the need for hundreds of individual trials throughout the U.S.
Link to blog: http://www.aboutlawsuits.com/xarelto-lawsuits-bleeding-do-not-slow-sales-81481/#sthash.8KFoM7p6.dpuf
-
Drug warnings withheld: Blood thinner causes uncontrolled bleeding
May 1, 2015 | Natural Health 365
By Allison Reed
Yet another highly marketed blood thinner medication, Xarelto, has been making headlines for its life-threatening side effects. In fact, Xarelto may be one of the most dangerous blood thinners to date – as there is no antidote for the internal bleeding it can cause individuals who take it. To make matter worse, the maker of Xarelto is under intense legal scrutiny for failure to warn the public about the risks including its serious potential for causing critical health issues. These problems have led multiple victims and their families to a Xarelto lawsuit, with many more expected to come. What you don’t know about Xarelto could be deadly It is impossible to know exactly how many people have been victimized by the deadly side effects of Xarelto. However, a quick look at any Xarelto lawsuit will reveal serious and sometimes fatal problems, such as gastrointestinal bleeding and even cerebral hemorrhaging. The maker of Xarelto marketed the drug as ‘safe and effective,’ despite data that showed people who took the drug had higher rates of blood transfusions and gastrointestinal bleeding than those taking other blood thinner medications like Warfarin. And, if you’re feeling the sensation of déjà vu, you’re not alone. This is exactly how the pharmaceutical industry responds to vaccine dangers or any other drug produced. Big pharma wants us to believe that everything is ‘alright’, as if nothing could go wrong with these toxic substances. Many people question the reasoning of Western medicine and the decision of physicians to wait until a person is at risk of heart disease or stroke to begin treating the condition. Prescribing dangerous drugs to manage the problem is like robbing Peter to pay Paul – someone always gets hurt. Instead of using hazardous blood thinner medication as the primary method of clot prevention, patients should instead be made aware of the many natural and non-toxic ways of thinning the blood. How to effectively improve blood circulation – without toxic side effects Fortunately, there are many natural ways to thin the blood without exposing oneself to the toxic effects of prescription blood thinner medications. In fact, many solutions can be found in the foods we eat. For example, researchers at Kansas State University found that garlic contains a powerful compound called ajoene, which has been found to help prevent blood platelets from forming clots. A person can easily enjoy the benefits of the ajoene compound by simply consuming a clove of raw or lightly cooked garlic daily. Garlic tea is also beneficial. Other foods with anti-clotting properties include turmeric and ginger. Both are widely used in cooking and help prevent clots from building along the walls of the arteries. In addition, ginger has been found to help lower cholesterol – an advantage that is often highly beneficial for people taking blood thinners who are at risk for heart attack. Another less common but effective strategy, you may want to add to your daily routine, is eating a few pieces of daikon (a mild-flavored white radish) – known for its ability to dissolve accumulated fat in the body. Don’t forget the importance of hydration for optimal health Of course, nature’s most powerful blood thinner medication is pure (clean) H2O. Water has absolutely no side effects and can be consumed in large quantities daily. It works by preventing dehydration, which can lead to blood thickening. Researchers at Loma Linda University studied men who drank water, finding that those who drank at least 40 ounces of water throughout each day cut their risk for forming clots and suffering stroke by more than half. Ideally, the average person should drink 0.5 ounces of water for every pound they weigh daily. Allow me to say the obvious, government-run health agencies and concerned politicians should not wait until there is another Xarelto lawsuit or new dangerous blood thinner on the market to stop herding the unsuspecting public into the pockets of the pharmaceutical industry. Patients (people) deserve to know what is going into their bodies and the potential for serious harm associated with blood thinners like Xarelto.
Link to blog: http://www.naturalhealth365.com/blood-thinner-medication-side-effects-of-xarelto-1406.html#sthash.3WzO5uMP.dpuf
-
Xarelto Lawsuit Added to Multidistrict Litigation
May 3, 2015 | Injury Lawyer News
By Stephanie Reid
On April 23, 2015, a new Xarelto lawsuit was filed in the ongoing multidistrict litigation (MDL) against the makers and manufacturers of the blood thinning agent: Janssen Pharmaceuticals and Johnson & Johnson. This lawsuit is one of dozens filed by injured plaintiffs or their families, all of which have alleged severe, unforeseen side effects associated with the drug.
Xarelto made its debut on the American pharmaceutical market in 2011 and has since been touted by drug makers and medical professionals as a convenient and effective alternative to the blood thinner warfarin. However, unlike warfarin, there is no known antidote available in the event a counterbalancing coagulant is needed, and many patients have alleged severe and unexpected internal bleeding episodes.Details of allegations against makers of Xarelto
Xarelto is prescribed primarily for the treatment of atrial fibrillation not caused by a heart valve malfunction. As well, patients afflicted with deep-vein thrombosis are also targeted by the “aggressive” marketing tactics utilized by Xarelto’s creators – which are two of the largest pharmaceutical companies in the world. According to these manufacturers, Xarelto eliminates the need for regular blood monitoring and dietary restrictions, which are to commonly-criticized components of treatment with the alternative warfarin.
The plaintiff in this most recent case began his Xarelto treatment in January, 2013, upon the advice of his physician during treatment for atrial fibrillation. In April, 2013, the plaintiff was suddenly admitted to the hospital where he was found to be bleeding internally – a dangerous side effect of Xareltoconsidering there is no antidote.
The plaintiff further reiterated his experience by detailing research and worldwide adverse reports associated with Xarelto, including:Seventy-two reported cases of death allegedly tied to Xarelto in GermanyApproximately 968 suspected undesirable side effectsSignificant reports of post-operative pulmonary embolisms, the very condition Xarelto is designed to preventHigher risks of gastrointestinal bleedsDefendants face allegations of negligence, failure to warn
When it comes to product liability involving prescription drugs, plaintiffs often allege a multitude of claims in order to effectuate maximum exposure to liability for the defendant(s) – and the Xarelto MDL is certainly no exception.
In this case, the plaintiff begins his allegations by contending the drug makers knew (or should have known) of the risks associated with the drug and failed to properly warn patients and physicians of the foreseeable danger.
As well, the plaintiff contends the drug was unreasonably dangerous in its design and manufacture, thereby exposing him to unnecessary risk.From there, the plaintiff asserts the following additional claims:NegligenceNegligent misrepresentation of the safety and effectiveness of XareltoBreach of express and implied warrantiesFraudViolation of consumer protection lawsPunitive damages
Accordingly, the plaintiff is seeking damages sufficient to compensate him for the expenses and expenditures directly and collaterally related to his experience with Xarelto. He is also seeking medical expenses, lost wages, and punitive damages to punish defendants for their alleged intentional misconduct.
On December 12, 2014, the United States Judicial Panel on Multi-District Litigation approved plaintiffs’ motion to centralize the 21 Xarelto lawsuits pending at the time. Over objection by defendants, the panel opted to consolidate the claims into MDL, and concluded the Eastern District of Louisiana would be an appropriate venue given its centralized experience and judicial experience with transferee cases.
Link to blog: http://injurylawyer-news.com/2015/05/xarelto-lawsuit-added-multidistrict-litigation/
-
Philadelphia Court System Establishes Xarelto Mass Tort
May 4, 2015 | Righting Injustice
By Jennifer Walker-Journey
Philadelphia’s court system has established a new Xarelto mass tort involving about 170 plaintiffs alleging uncontrollable and sometimes fatal bleeding with theblood thinning drug. The lawsuits name Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals as the defendants.
The city’s first Xarelto side effects lawsuit was filed in the Philadelphia Court of Common Pleas in February 2014 and since then the cases have been mounting. In November 2014, 19 new cases were filed followed by 26 in December, 17 in January 2015, 37 in February and 50 in March. Some attorneys suspect more cases will follow once it is known where the multidistrict litigation goes.
A Xarelto side effects multidistrict litigation was also established in January in Louisiana federal court in the Eastern District of Louisiana. Since the Xarelto mass tort is relatively young and there are not statute of limitations issues, legal experts say that time is on their side to fully vet and screen prospective plaintiffs.
Xarelto is considered a “next generation” blood thinner designed to prevent and treat blood clots in patients who recently underwent knee or hip replacement surgery, or to prevent strokes and blood clots in some heart patients. It was designed to be a more convenient alternative to the long-used warfarin, which requires patients to be monitored on a regular basis.
Since it was approved in 2011, Xarelto has grown to a blockbuster medication with more than $2 billion in sales thanks to the drug companies’ marketing efforts. Yet the promotion of Xarelto did not effectively cover the drug’s bleeding side effects. According to the mass tort petition, by the end of 2012, 2,080 Xarelto-related injuries, including 151 deaths, had been associated with the blood thinner.
There is also no reversal agent to stop the blood thinning effects of Xarelto, as there is with warfarin.
Attorneys for the drug companies say a mass tort in Philadelphia was inappropriate because almost all of the plaintiffs are from other states and could go into the multidistrict litigation.
Link to blog: http://www.rightinginjustice.com/news/2015/05/04/philadelphia-court-system-establishes-xarelto-mass-tort/
-
Ind. Man Sues Pharmaceutical Giants for Xarelto Bleeding Injury
May 4, 2015 | Top Class Actions
By Amanda Antell
Indiana plaintiff Frederick B. is suing Bayer and Janssen Pharmaceuticals for the injuries he allegedly sustained from their anticoagulant product. Frederick claims that as a direct result of using Xarelto, he developed severe gastrointestinal bleeding.
Sometime in early 2013, Frederick was prescribed Xarelto to treat his atrial fibrillation by his physician, who had reviewed the defendant’s advertisements and favorable Xarelto medical studies, according to the Xarelto lawsuit. At all times while using Xarelto, Frederick allegedly followed all prescription instructions, along with the advice of his physician. However, this diligence allegedly did not protect Frederick from an internal bleeding event that occurred on May 7, 2013.
On this date, Frederick was diagnosed with severe gastrointestinal bleeding and required hospital intervention. His physician and other medical staff determined that it was likely the bleeding event was caused by an anticoagulant, based on diagnostic testing. While Frederick survived this ordeal, other patients cannot say the same as the FDA has received dozens of death reports linked to Xarelto, as well as other anticoagulants. It is important to note that other than Warfarin, anticoagulants like Xarelto currently have no reversal agents to stop internal bleeding.
Despite the severity of Xarelto risks, Janssen and Bayer allegedly chose to omit this information from Xarelto’s label. Even if the information was present on the drug’s label, the plaintiff states that the label did not adequately explain the risks of Xarelto bleeding, and neglected to mention the lack of a Xarelto bleeding antidote. After learning of the associated bleeding injuries, Frederick has taken legal action against the pharmaceutical giants.
Frederick further claims in the Xarelto lawsuit that the drug companies failed to protect him and other patients from the defects of their product, and failed to warn him against the risk of Xarelto bleeding injuries. Frederick’s lawyers claim that the defendants had the responsibility to warn their client and other Xarelto patients of the side effects of their drug, because they rely on the accuracy of the given information.
Frederick insists that he never would have used Xarelto if he has been informed about the risk of gastrointestinal bleeding. So for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug, Frederick is suing Janssen Pharmaceuticals and Bayer Pharmaceuticals. The charges include: negligence, false advertising, concealing information, and misrepresenting a product.
Xarelto Complications
Xarelto was approved by the FDA on July 1, 2011, joining the anticoagulant market alongside Pradaxa and Warfarin. Similarly to Pradaxa, which was released the year previously, Xarelto is designed to treat patients with certain blood-clotting conditions like atrial fibrillation and is typically prescribed to patients who are at a high risk of experiencing stroke.
Since its release, Xarelto has dominated the anticoagulant market with sales garnering billions for its manufacturing companies Bayer Pharmaceuticals and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). Xarelto is a part of the new generation anticoagulants that was meant to compete against Warfarin and is projected to be the 19th best-selling drug in the world by the year 2018. Along with other new generation blood thinners, Pradaxa and Eliquis, approved in 2012, Xarelto was advertised to be overtly superior to Warfarin with its fast-acting treatment mechanism and hassle-free prescription.
As mentioned before, Warfarin is the only anticoagulant with an approved internal bleeding remedy. However, Warfarin also requires patients to regularly see their doctors and undergo frequent dose adjustments and monitoring. Legal experts believe that if the newer anticoagulants, like Xarelto, had these same requirements, then numerous bleeding injuries could have been reported, even without a bleeding antidote.
The Xarelto Lawsuit is Case No. 3:15-cv-00857-W-WVG, in the U.S. District Court for the Southern District of California.
Link to blog: http://topclassactions.com/lawsuit-settlements/lawsuit-news/55018-ind-man-sues-pharmaceutical-giants-for-xarelto-bleeding-injury/
-
Xarelto Medication Lawsuits Pending in MDL Reach 402 as of April 17, 2015
May 5, 2015 | American Injury Attorney Group
By Staff
Lawsuits involving Janssen’s Xarelto medication continue to move forward. According to court records, 100 Xarelto lawsuits have been filed since March 16, 2015 in the Xarelto multidistrict litigation (MDL) in the U.S. District Court, Eastern District of Louisiana. According to the U.S. Judicial Panel on Multidistrict Litigation, as of April 17, 2015, 402 lawsuits are pending in the Xarelto MDL.
If you or a loved one took Xarelto and suffered complications, contact the American Injury Attorney Group today for more information about your options. We can answer your questions, and if you have a case, we can connect you with an affiliated attorney. The time to pursue a claim is limited, so contact us today.50 Xarelto Lawsuits Added to Pennsylvania Mass Tort in March 2015
In addition to Xarelto medication cases pending in the federal MDL, an April 23, 2015 Case List released by the Philadelphia Court of Common Pleas in Pennsylvania shows that at least 204 Xarelto lawsuits are pending in Pennsylvania’s state court mass tort proceeding. In March 2015, 50 lawsuits were added to that proceeding, and the claims allege that Xarelto is associated with severe internal bleeding and related complications, including pulmonary embolism, deep vein thrombosis, and stroke.
Attorneys note that during its first 12 months on the market, Xarelto medication was named in 2,081 adverse event reports that were submitted to the U.S. Food and Drug Administration. 151 reported deaths were attributed to the product. In comparison, a long-standing blood thinning medication on the market, warfarin, was named in only 56 reported deaths out of 861 total adverse event reports. Consolidated litigation in both Louisiana federal court and Pennsylvania state court were established to allow cases in which plaintiffs have similar complaints to move more efficiently through the courts.
Patients who suffered severe complications from Xarelto medication may be entitled to compensation for medical expenses, pain and suffering, and other losses. Family members of those who died as a result of taking the medication may be entitled to wrongful death damages. Those who are interested in pursuing a claim for compensation are encouraged to learn their options today, as state laws limit the time each patient has to pursue a claim.The Time to Pursue a Claim is Limited. Contact Us Today.
If you or a loved one took Xarelto medication and suffered complications, including uncontrolled bleeding, contact the American Injury Attorney Group to learn more about your options. We offer free, no-obligation consultations, and if you have a case, we can connect you with an affiliated Xarelto lawsuit attorney who can help you seek the compensation to which you may be entitled. The time to pursue a claim is limited, so contact us today.
Link to blog: https://attorney-group.com/blog/xarelto-medication-lawsuits-pending-in-mdl-reach-402-as-of-april-17-2015/
-
The Choice between Xarelto Bleeding and Stroke Risks
May 6, 2015 | Legal Examiner - Pennsylvania
By Gregory Spizer
People with atrial fibrillation have an increased risk of suffering a stroke. Taking blood thinner drugs can decrease the risk, but some of these medications are not without the risks of internal bleeding. Popular blood-thinning drug Xarelto is prescribed to patients to prevent blood clots and prevent strokes. Most patients do not know that Xarelto may also cause irreversible internal bleeding, often resulting in extended hospitalizations and death.
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in July 2011, for patients with atrial fibrillation not caused by a heart-valve problem. Patients taking anticoagulants, such as Xarelto significantly lower their stroke risk, but they can experience bleeding more easily. Significantly, there is no known antidote (cure) to reverse the type of internal bleeding caused by Xarelto, unlike other blood thinners like Warafin (generic form of Coumadin).
Janssen Pharmaceuticals touted Xarelto as an alternative to other blood thinners with an added benefit: Xarelto, according to the manufacturer, doesn’t require blood monitoring. However, failure to monitor a patient’s blood levels while taking Xarelto can lead to irreversible internal bleeding and result in serious injury, or death. Patients taking Xarelto and other blood thinners should not discontinue use of the drug without consulting their physician. People with atrial fibrillation should discuss the safest and most effective treatments with their doctor as well as the appropriate level of blood monitoring.
Anyone injured by Xarelto bleeding may be eligible to file a lawsuit not only to seek compensation, but also to make the manufacturer take responsibility for putting patients in serious danger. Contact a Xarelto lawyer to preserve your legal rights if it happened to you or a loved one.
Link to blog: http://central-pennsylvania.legalexaminer.com/fda-prescription-drugs/the-choice-between-xarelto-bleeding-and-stroke-risks/
-
Xarelto Cases Have Been Consolidated in Louisiana
May 6, 2015 | DGMS Law
By Staff
You may have seen the commercials for Xarelto – the ones with Arnold Palmer, Kevin Nealon, and and Brian Vickers. Xarelto is a blood thinner used to prevent blood clots. It’s a fairly new drug and, unfortunately, has some dangerous side effects. The worst of these is uncontrolled bleeding, which can be fatal. Hundreds of Xarelto users suffering from uncontrolled bleeding and its dangerous consequences have filed suit against Janssen Pharmaceuticals, Inc. (a unit of Johnson & Johnson) and Bayer, the makers of Xarelto. Late last year, many of those cases were consolidated into an MDL in Louisiana.WHAT’S THE CASE AGAINST XARELTO?
Xarelto (rivaroxaban) is a blood thinner, similar to warfarin (Coumadin) and heparin. While warfarin and heparin have been around for decades, Xarelto was approved by the FDA less than 5 years ago. Many patients and doctors prefer it to the older drugs because it’s easier to take. Other blood thinners require lifestyle and diet changes in addition to regular blood tests while Xarelto does not.
All blood thinners have some side effects, but the most dangerous one is typically uncontrolled bleeding. The blood is thinner so it won’t form blood clots, but that also means your body can’t seal off scrapes and other injuries quickly. People on blood thinners may bruise more easily than usual and may find that cuts and scrapes continue to bleed for longer than normal. Most of the time this is merely inconvenient, but in certain circumstances it can be very dangerous. If the dose of blood thinner is too high, it’s possible to experience serious bleeding from minor bumps. If someone on blood thinners experiences a trauma such as a car accident, she is at a much higher risk for internal bleeding.
When your blood won’t clot, what can you do to stop the bleeding? Warfarin and heparin have antidotes. The doctors can give you the antidote to get your blood consistency back to a healthy level. Xarelto, however, has no antidote. Some drugs can be removed from your body by running your blood through a dialysis machine, but that doesn’t work on Xarelto either. There’s no way to stop the bleeding and no way to get the drug out of your system until it wears off on its own. As a result, hundreds of Xarelto users have suffered from uncontrolled bleeding; some cases have been fatal.
So, Xarelto users who have suffered from uncontrolled bleeding have started to bring suit against the makers of Xarelto for failing to adequately warn them about the dangers of using a blood thinner that has no antidote. Pharmaceutical companies have a duty to warn consumers and doctors about risks and side effects; that’s part of the reason an FDA label is so long and detailed. If the makers of a drug fail to warn consumers and doctors about risks that the company knew or should have known about, they’ll be required to pay compensation to those hurt by the drug.THE XARELTO MDL
In some cases where a large number of people are hurt by the same cause, that group of people can sue together in a class action lawsuit. The class sues together and every member shares in the outcome. However, it’s very difficult to form a legally recognized class. So far, there is no recognized class of Xarelto users. However, it doesn’t make sense for every single person harmed by a drug to sue the pharmaceutical company alone. The injured consumers may not have the resources for such a lawsuit and different courts could reach different decisions on similar cases, which would be unfair. That’s where a Multi-District Litigation (MDL) comes in.
An MDL allows a large number of individual cases to benefit from some of the streamlined class action process without actually becoming a class. In an MDL, a large number of cases are consolidated into one big proceeding for the pre-trial portions of the case. That includes the pre-trial motions, discovery, and settlement conferences. Pre-trial motions can encompass a range of issues, but essentially boil down to whether or not there is a case. The MDL is most useful to plaintiffs in the discovery phase. Both sides only have to go through the discovery process (where each side gets the evidence they need) one time and every plaintiff gets the benefit of all the available evidence.
An MDL is used to determine common questions of fact for large numbers of cases. In other words, the MDL proceeding determines what happened. During the MDL process, some cases may settle. The cases that don’t settle at the MDL stage then return to their appropriate jurisdictions individually for their own trials. The trials will determine questions of law; that means applying the right laws to the facts decided upon in the MDL.
To illustrate, let’s consider an fictional case between a group of plaintiffs and a pharmaceutical company called Drug, Inc. For a lawsuit over a dangerous drug, the plaintiffs will often need to show that the makers of the drug knew or should have known about the risks associated with using the drug. In order to prove that to the court, the plaintiffs will need evidence such as internal documents, clinical testing results, and depositions from key people at the drug company. The MDL process allows all this information to be gathered just one time, rather than forcing every plaintiff to obtain it individually. The plaintiffs will then present that evidence and the MDL court will decide, as a matter of fact, whether Drug, Inc. knew or should have known about the risks. Let’s say the MDL court decides that Drug, Inc. did, in fact, know about the risks. When the plaintiffs go back to their own jurisdictions for their own trials, that will be included as an inarguable fact in each case.
Because the actual trials happen in different jurisdictions and because individual facts may differ (like the health condition of the plaintiff, for example), the outcomes of each case may be different. However, all the cases involved in the MDL get the benefit of the common facts decided at the MDL level.
The Xarelto case has been consolidated into an MDL in Louisiana and will be heard by the Honorable Eldon E. Fallon.WHY DOES IT MATTER TO XARELTO USERS?
Xarelto users involved in the MDL will have the benefit of a larger resource pool with which to get the evidence they need. The discovery portion of the trial, in which both side gather their evidence, can be extremely expensive and time-consuming. In a case about a dangerous drug, it may also require a lot of expensive expert testimony and depositions of all the people involved. An MDL is a way for people who couldn’t afford the high legal fees on their own to get the compensation they deserve.
Even if you haven’t filed suit yet, your case can be added to the MDL. That’s called a “tag-along” case.HAVE YOU BEEN INJURED BY XARELTO?
If so, you may be entitled to compensation. Remember that the law in Ohio limits the amount of time you have to file a claim, so don’t wait. Contact us today to speak to one of our experienced dangerous drug attorneys for a free case evaluation and consultation. We can help you fight for the compensation you deserve.
Link to blog: http://www.ohiotiger.com/xarelto-cases-have-been-consolidated-in-louisiana/
-
Research Suggests Gastrointestinal Xarelto Side Effects Worse Than Warfarin’s
May 7, 2015 | Injury Lawyer News
By Sarah May
According to a recently published research study, popular anticoagulant drugs Xarelto and Pradaxa may pose a heightened risk of serious gastrointestinal bleeding in patients who choose them instead of more traditional blood thinning medications such as warfarin.
The study, undertaken by researchers from Johns Hopkins Bloomberg School of Public Health and George Washington University and published on April 24 in the British Medical Journal (BMJ), shows that Xarelto may present double warfarin’s risk of gastrointestinal bleeds and Pradaxa may boost the danger by upwards of 50% over warfarin.Study raises more doubts about safety of Xarelto
The authors of this latest study reviewed information on over 46,000 patients who were given one of the three major anticoagulant drugs (Xarelto, Pradaxa or warfarin) during the period of October 2012 through March 2012. The research was initiated in order to explore ongoing issues with new generation blood thinning medications and compare them to more conventional treatments.
Warfarin is a drug that has long been used to reduce the risk of stroke in patients diagnosed with atrial fibrilation, but Xarelto and Pradaxa have recently been touted as much better, more convenient options for patients with that condition. However, the newer drugs have increasingly been suspected of causing serious, uncontrolled bleeding events in thousands of individuals. Whereas the blood thinning mechanism of warfarin can quickly and easily be reversed by introducing vitamin K, no such antidote currently exists for Xarelto or Pradaxa. Therefore, once a bleeding event linked to these drugs begins, there is often nothing doctors can do to halt it.
The researchers behind this study emphasize that their results do not prove a statistically significant increase in bleeding risk between either of the new anticoagulants and warfarin, they also underscore the fact that they could not rule out the existence of elevated risks resulting from warfarin use as opposed to the use of Pradaxa or Xarelto. This is in keeping with multiple other studies suggesting an increase in bleeding risk posed by these modern blood thinning agents.Xarelto litigation continues course
Since their respective market debuts, Pradaxa and Xarelto have been the subject of an alarming number of adverse event reports made to the U.S. Food and Drug Administration and have formed the basis of thousands of new lawsuits. Boehringer Ingelheim, maker of Pradaxa, faced over 4,000 plaintiffs in litigation who claimed that the drug giant failed to provide adequate warning of known risks of the drug while selling and marketing a defectively dangerous product. Ultimately, the company agreed to roughly$650 million in settlement payments to those impacted.
Lawsuits related to severe, sometimes fatal Xarelto side effects are also being filed in large numbers in courts across the country. Many of the claimants allege that Janssen Pharmaceuticals and Bayer Healthcare Pharmaceuticals fraudulently misrepresented the drug’s safety, withheld information regarding known risks and did not provide sufficient warnings about the drug’s lack of an antidote.
Though it was just announced that Boehringer Ingelheim has won FDA Priority Review of a possible antidote for Pradaxa, it seems all but certain that controversy, litigation and consumer watchdog concern about new generation anticoagulant drugs will persist for the foreseeable future.
Link to blog: http://injurylawyer-news.com/2015/05/research-suggests-gastrointestinal-xarelto-side-effects-worse-warfarins/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
Full Text of Stories Below
Add recipients
Suggested